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Abstract
AIM: To investigate the correlations between self-
reported symptoms of irritable bowel syndrome (IBS) 
and the gastrointestinal (GI) microbiota composition.
METHODS: Fecal samples were collected from a total 
of 44 subjects diagnosed with IBS. Their symptoms 
were monitored with a validated inflammatory bowel 
disease questionnaire adjusted for IBS patients. Thirteen 
quantitative real-time polymerase chain reaction assays 
were applied to evaluate the GI microbiota composition. 
Eubacteria and GI bacterial genera (Bifidobacterium , 
Lactobacillus  and Veillonella ), groups (Clostridium coc-
coides/Eubacterium rectale , Desulfovibrio desulfuricans) 
and distinct bacterial phylotypes [closest 16S rDNA se-
quence resemblance to species Bifidobacterium catenu-
latum , Clostridium cocleatum , Collinsella aerofaciens  
(C. aerofaciens ), Coprococcus eutactus  (C. eutactus ), 
Ruminococcus torques  and Streptococcus bovis ] with a 
suspected association with IBS were quantified. Correla-
tions between quantities or presence/absence data of 
selected bacterial groups or phylotypes and various IBS-
related symptoms were investigated.
RESULTS: Associations were observed between sub-
jects’ self-reported symptoms and the presence or quan-
tities of certain GI bacteria. A Ruminococcus torques  
(R. torques)-like (94% similarity in 16S rRNA gene se-
quence) phylotype was associated with severity of bow-
el symptoms. Furthermore, among IBS subjects with 
R. torques  94% detected, the amounts of C. cocleatum 
88%, C. aerofaciens -like and C. eutactus 97% phylo-
types were significantly reduced. Interesting observa-
tions were also made concerning the effect of a subject’s 
weight on GI microbiota with regard to C. aerofaciens -
like phylotype, Bifidobacterium spp. and Lactobacillus  
spp.
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CONCLUSION: Bacteria seemingly affecting the symp-
tom scores are unlikely to be the underlying cause or 
cure of IBS, but they may serve as biomarkers of the 
condition. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a common functional 
bowel disorder, with an estimated worldwide preva-
lence of  10%-20% among adults and adolescents. IBS 
is characterized by pain or discomfort, distorted bowel 
habits and altered stool characteristics[1]. Although the 
prognosis of  IBS is good, the syndrome results in a 
reduced quality of  life. Subjects with IBS report signifi-
cantly more comorbidities, including dyspepsia, asthma 
and head- and backache, as well as anxiety, depression 
and insomnia, than the general population[2]. The exact 
etiology of  IBS is likely to be multifactorial; moreover, 
patients diagnosed with the disorder may well be experi-
encing bowel symptoms due to different causes. 
Much attention has recently been focused on the 
impact of  gastrointestinal (GI) microbiota on this dis-
order. Changes observed in the fecal microbiota com-
position[3-5], high incidence of  IBS after GI infections[6], 
alterations seen in IBS patients’ GI immune systems[7], 
as well as ability of  probiotics to alleviate the symptoms 
of  IBS[8-10], all suggest that microbes play a key role in 
IBS. However, a genetic basis for IBS has also been pre-
sented. In twin studies, a greater likelihood for a twin to 
develop IBS if  the other sibling already had the disorder 
was observed among monozygotic twins compared to 
dizygotic twins[11]. Upregulation of  genes involved in 
mucin production has been described to take place in 
IBS patients[12]. Downregulation of  protease-activated 
receptor 1 expression and upregulation of  protease-
activated receptor 2 ligand mast cell tryptase in diarrhea-
predominant IBS (IBS-D) are involved in visceral hyper-
sensitivity; a change in the expression ratio of  these two 
protease-activated receptors appears to take place in the 
context of  IBS-D[13]. Similarly to ulcerative colitis, colon-
ic mucosal 5-HT (serotonin) concentrations are signifi-
cantly lowered in IBS patients compared with the levels 
observed in healthy controls, suggesting the existence of  
a shared mechanism underlying the symptoms[14]. 
In this study, we examined whether the presence or 
absence of  certain microbes previously linked to either 
IBS or healthy controls’ microbiota correlated with the 
symptoms experienced by IBS patients. Our results sug-
gest that a connection between IBS-related microbiota 
and severity of  self-reported symptoms exists.
MATERIALS AND METHODS
Subjects
Subjects fulfilling the Rome I criteria for IBS[15] were re-
cruited from the district of  Kuopio in Eastern Finland 
by the Kuopio University Hospital and Harjula Hospital 
during years 2004-2005. The participants (n = 44; 11 
men, 33 women) were 20-72 years old and their general 
condition was confirmed as good by medical experts (see 
Table 1 for subject characteristics). Exclusion criteria for 
participation included presence of  organic GI diseases, 
inadequately treated hypertension or pharmaceutically 
treated diabetes. Use of  statins, pharmaceutically treated 
hypertension or coronary artery disease were not consid-
ered exclusion criteria if  medication had been used for 
at least six months prior to the study with no changes in 
dosage.
Clinical studies and laboratory tests
Participants were subjected to a standard medical exami-
nation and laboratory tests, including blood cell counts 
(B-Leuk, B-Trom, B-Eryt), hemoglobin (B-Hb), hema-
tocrit (B-Hcr), erythrocyte mean cell volume (E-MCV), 
mean cell hemoglobin (E-MCH) and mean corpuscular 
hemoglobin concentration (E-MCHC), erythrocyte sedi-
mentation rate, glycosylated hemoglobin (B-GHbAlc) and 
blood lipids (fS-Chol, fS-Chol-HDL, S-Trigly). Lactose 
absorption was ensured with a DNA test for a mutation 
in the lactase gene. The participants were also tested for 
the presence of  IgA antibodies against gliadin, followed 
by a duodenal biopsy if  celiac disease was suspected. 
Subjects over 45 years were examined for the presence 
of  carcinoembryonic antigen (CEA). In addition, pres-
ence of  occult blood in the feces was evaluated.
Questionnaires
Participants filled in a questionnaire regarding their qual-
ity of  life and symptoms. The survey was based on an 
internationally approved and validated questionnaire for 
inflammatory bowel disease questionnaire (IBDQ)[16]. 
The questions in the IBDQ were adapted to suit IBS pa-
tients. The query contained 30 questions clustered into 
four groups, comprising “bowel symptoms”, “systemic 
symptoms”, “social function” and “emotional function”. 
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The seven alternative answers for each question were as-
signed numerical values from 1 to 7 (1 = no problem at 
all, 7 = very severe problem). Two questions regarding 
the form of  feces and the frequency of  defecation were 
treated as separate variables. The participants also an-
swered two questions about prior antibiotic treatments 
and GI infections.
Analysis of fecal bacterial microbiota 
Each subject gave a fecal sample for bacteriological stud-
ies. The samples were stored at -80℃ prior to analysis. 
Bacterial DNA was isolated from 1 g of  fecal material by 
removing the undigested particles from the fecal material 
with three rounds of  low-speed centrifugation, collec-
tion of  the bacterial cells with high-speed centrifugation, 
enzymatic and mechanical cell lysis and DNA extraction 
and precipitation[17]. DNA concentrations were measured 
with the multilabel plate reader Victor3TM (PerkinElmer 
Life and Analytical Sciences, Boston, MA, USA). With 
the method, the average yield of  DNA was 342 μg/g of  
fecal material (median: 290 μg/g, SD: 167 μg/g). Quan-
titative real-time polymerase chain reaction (qPCR) was 
used to assess the amounts of  selected GI bacteria or 
bacterial phylotypes (Table 2) in the fecal samples. 
In total, 13 qPCR assays were performed to analyze 
the GI microbiota in fecal samples (Table 2). The applied 
assays targeted quantitatively IBS-associated human GI 
bacteria (Lactobacillus spp., Clostridium coccoides/Eubacterium 
rectale-group, Veillonella spp. and Bifidobacterium spp.)[5] and 
bacterial phylotypes [Collinsella aerofaciens-like, Clostridium 
cocleatum 88%, Coprococcus eutactus 97%, Ruminococcus torques 
91% and Ruminococcus torques (R. torques) 94%][4,18] or bac-
teria associated with IBS in semi-quantitative sequence 
data analyses (Bifidobacterium catenulatum/Pseudocatenulatum-
like)[4] or with intestinal disturbances according to the 
literature (Desulfovibrio desulfuricans-group)[19]. The iCycler 
iQ Real-Time Detection System (Bio-Rad, Hercules, 
CA, USA) in conjunction with the iCycler Optical Sys-
tem Interface software (version 2.3; Bio-Rad) were used 
to analyze the samples as described previously[4,5]. Two 
technical replicates were used for the samples and stan-
dard reactions. Depending on the assay, 0.5 or 50 ng of  
fecal DNA was applied in the reactions. 
Statistical tests
Basic statistical analysis of  the data was performed using 
the SPSS program, version 14.0 (SPSS Inc., Chicago, IL, 
USA). R program, version 2.8.0[20] and the package Rc-
mdr, version 1.4-10[21] were used to perform the princi-
pal component analysis (PCA), to describe the categori-
cal data and to statistically test this data. Linear models 
were used to describe the relationship between variables 
and were applied to each bacterial genus and phylotype 
quantified.
The health-related quality of  life questionnaire yielded 
ordinal data; thus, non-parametric statistical methods were 
used for analysis. However, PCA analysis was performed 
for the questionnaire data. Results are presented as me-
dians and interquartile ranges. The c2 test was applied to 
compare nominal data, and the Mann-Whitney U test to 
compare continuous data when two patient groups were 
analyzed. 
Logarithmic transformation was performed on the 
bacterial data prior to further analyses. Within the data, 
undetected abundances possibly caused by technical limi-
tations instead of  the absence of  the target phylotype 
were imputed with the mean values obtained from the 
qPCR runs with the same primer applied to water. If  these 
also were undetected for a certain assay, the minimum 
of  all detected water runs was used. Bacterial qPCR data 
were also inspected to ascertain the presence or absence 
of  certain phylotypes in the patient samples. Binary data 
were then used to evaluate whether the phylotypes had 
any relationship with various traits of  the study subjects.
Ethical issues
The study protocol was approved by the Kuopio Uni-
versity Hospital Ethical Committee. Participation in the 
study was voluntary, and patients were allowed to with-
draw at any point without giving an explanation. 
RESULTS
Characteristics of IBS patients
Characteristics of  the IBS patients are listed in Table 1. 
In general, the clinical studies revealed no major issues 
regarding the health status of  participants. However, of  
the 44 subjects studied, 7/11 men and 15/33 women 
had a body mass index (BMI) value above 25, which 
is considered borderline between normal weight and 
slightly overweight[22]. Presence of  Helicobacter had been 
confirmed previously in 8 patients; interestingly, in some 
cases, treatment of  the infection had remained incom-
plete (data not shown). Helicobacter infection or the way 
it had been treated was not, however, reflected in the 
symptoms (data not shown). Origin of  IBS as a result of  
GI inflammation was not given support by this study, as 
only one subject recalled suffering from gastroenteritis 
but could not remember whether the onset of  IBS oc-
curred before or after the ailment. 
Bacterial analyses and correlation of symptom scores 
with microbiota composition
The modified IBDQ symptom questionnaire consisted 
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Table 1  Characteristics of the study subjects
Characteristic mean ± SD Median (range)
Age (yr)    48.4 ± 11.9 49.0 (20-72)
Body mass index (kg/m2)  26.3 ± 5.1       26.0 (19.4-45.6) 
Systolic blood pressure (mmHg)  129.2 ± 19.1 129.5 (95-175)
Diastolic blood pressure (mmHg)    83.0 ± 10.2   83.5 (61-100)
Hemoglobin (g/L)  139.0 ± 12.0   139.0 (108-165)
B-GHba1c (%)      5.6 ± 0.38     5.6 (4.8-6.4)
Total cholesterol (mmol/L)      5.1 ± 0.73     5.0 (3.8-7.3)
Sedimentation rate (mm/h)    7.4 ± 7.1 5.0 (2-43)
of  28 questions divided into the four categories of  bowel 
symptoms, systemic symptoms, social function and emo-
tional function (Table 3). High median values along with a 
narrow interquartile range can be considered characteristic 
of  the questions central for ascertaining symptoms of  IBS 
(Table 3). Correlations between the four categories were 
all significant (Table 4).
Abundance and prevalence of  the 13 qPCR target bac-
teria or phylotypes in patient samples are shown in Tables 5 
and 6, respectively. An association between R. torques 94% 
phylotype and symptom scores (emotional function, so-
cial function, systemic symptoms, bowel symptoms) was 
observed in a PCA visualization of  the results as they cor-
related significantly with the same dimension, whereas a 
weaker negative association was observed for Coprococcus 
eutactus (C. eutactus) 97%, Bifidobacterium spp., Veillonella spp. 
and Desulfovibrio desulfuricans (D. desulfuricans)-group and the 
symptom scores (Figure 1A). When the bowel symptoms 
(bloating, passing gas, increased need to defecate or need 
to defecate when bowel is empty, abdominal cramps, ab-
dominal pain, soiling) were analyzed in a PCA, a similar 
effect was observed: R. torques 94% and all bowel symp-
toms except soiling correlated with the same dimension, 
whereas Collinsella aerofaciens (C. aerofaciens)-like, C. eutactus 
97%, Veillonella spp., Bifidobacterium spp., and Lactobacillus 
spp. were negatively associated (Figure 1B).
In linear modeling of  continuous data, R. torques 94% 
was associated with an increase in self-reported bowel 
symptoms [analysis of  variance (ANOVA), P < 0.05]. 
When the IBS subjects were grouped according to whether 
R. torques 94% was detected in their fecal samples (Table 7), 
self-reported bowel symptoms tended to be higher among 
subjects with R. torques 94% present (ANOVA, P = 0.056). 
Interestingly, presence of  R. torques 94% had a negative 
effect on the abundance of  C. eutactus 97% (P < 0.01), 
C. aerofaciens-like (P < 0.05) and C. cocleatum 88% (P < 0.05) 
phylotypes. 
No other bacterial associations with symptom scores 
could be verified. Although in particular the C. aerofa-
ciens-like phylotype had a negative association with R. 
torques 94%, its relationship with self-reported symptoms 
remained obscure. The phylotype was, however, associ-
ated with lower BMI values (Mann-Whitney test for 
present-absent data; P < 0.01) and lower blood pressure 
(Mann-Whitney test for present-absent data for systolic 
and diastolic blood pressure; P < 0.01 and 0.01, respec-
tively), and the data also suggested a link to lower blood 
sugar levels (P = 0.06). The C. aerofacien-like phylotype 
was less frequently observed in subjects with BMI above 
25 (Table 6) and none of  the six subjects with BMI val-
ues over 30 had the C. aerofaciens-like phylotype in their 
feces. Similary to C. aerofaciens, C. eutactus 97% was also 
associated with lower blood pressure (P < 0.05 and 0.05 
for diastolic and systolic blood pressure, respectively). A 
positive association was present between the presence of  
C. aerofaciens and amounts of  C. eutactus 97% (P < 0.01), 
whereas a strong negative effect on R. torques 94% was 
observed (P < 0.001). In addition, when the IBS subjects 
were categorized according to their BMI, subjects with a 
BMI value over 25 had more bifidobacteria than normal-
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Table 2  Targets, assay conditions and primers of quantitative real-time polymerase chain reaction assays
Target bacterial group/phylotype Positive control strain or clone MgCl2 
(mmol/L)
Detection 
(℃)
Annealing 
(℃)
Primer sequences (F: forward, R: reverse)
Bifidobacterium catenulatum/
Pseudocatenulatum-like[4]
AM277302 3 87 68 F: 5'-ACTCCTCGCATGGGGTGTC-3'
R: 5'-CCGAAGGCTTGCTCCCGAT-3'
Bifidobacterium spp.[30] Bifidobacterium longum 3 85 58 F: 5'-TCGCGTC(C/T)GGTGTGAAAG-3'
DSM20219 R: 5'-CCACATCCAGC(A/G)TCCAC-3'
Clostridium coccoides/Eubacterium 
rectale-group[30]
Ruminococcus productus 4 85 55 F: 5'-CGGTACCTGACTAAGAAG-3'
R: 5'-AGTTT(C/T)ATTCTTGCGAAC-3'DSM2950
Clostridium cocleatum 88%[4] AM275477 4 80 60 F: 5'-AATACATAAGTAACCTGGCRTC-3'
R: 5'-CGTAGCACTTTTCATATAGAGTT-3'
Collinsella aerofaciens-like[4] AM276364 4 89 67 F: 5'-CCCGACGGGAGGGGAT-3'
R: 5'-CTTCTGCAGGTACAGTCTTGAC-3'
Coprococcus eutactus 97%[4] AM278899 2 83 63 F: 5'-AGCTTGCTCCGGCYGATTTA-3'
R: 5'-CGGTTTTACCAGTCGTTTCCAA-3'
Desulfovibrio desulfuricans-group[30] Desulfovibrio desulfuricans 4 85 58 F: 5'-GGTACCTTCAAAGGAAGCAC-3' 
ATCC7757 R: 5'-GGGATTTCACCCCTGACTTA-3'
Eubacterial 16S[31] Bifidobacterium longum 3 80 50 F: 5'-TCCTACGGGAGGCAGCAGT-3'
DSM20219 R: 5'-GGACTACCAGGGTATCTAATCCTGTT-3'
Lactobacillus-group[32,33] Lactobacillus acidophilus 2 85 58 F: 5'-AGCAGTAGGGAATCTTCCA-3'
ATCC4356 R: 5'-CACCGCTACACATGGAG-3'
Ruminococcus torques 91%[4] AM276624 5 82 62 F: 5'-TGCTTAACTGATCTTCTTCGGA-3'
R: 5'-CGGTATTAGCAGTCATTTCTG-3'
Ruminococcus torques 94%[4] AM277929 2 85 65 F: 5'-AATCTTCGGAGGAAGAGGACA-3'
R: 5'-ACACTACACCATGCGGTCCT-3'
Streptococcus bovis-like[4] AM276479 5 80 60 F: 5'-TTAGCTTGCTAAAGTTGGAA-3'
R: 5'-ATCTACTAGTGAAGCAATTGCT-3'
Veillonella spp.[30] Veillonella parvula 
ATCC10790
3 85 62 F: 5'-A(C/T)CAACCTGCCCTTCAGA-3'
R: 5'-CGTCCCGATTAACAGAGCTT-3'
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weight subjects, but less lactobacilli in an almost signifi-
cant manner (Table 5).
DISCUSSION
Self-reported symptoms and GI microbiota composition 
of  IBS patients were analyzed to investigate putative 
biomarkers for the disorder. Interesting associations be-
tween GI microbiota composition and symptom severity 
were observed. 
To measure IBS patients’ symptoms, we applied the 
IBDQ, designed for assessing the quality of  life of  IBD 
patients[16], with some modifications for IBS patients. 
According to the Spearman’s correlations calculated for 
each question and symptom group, the questions gener-
ally described best the group in which they were included 
(data not shown). Generally, the range observed for each 
question contained the entire available scale, indicating 
that the patients formed a heterogeneous group regarding 
the severity of  individual symptoms (Table 3). However, 
between symptom groups, there were high correlations, 
indicating that although the questions measured severity 
of  specific issues, the groups themselves actually measured 
the same health issues (Table 4). This is understandable 
since IBS patients’ physical and mental symptoms reflect 
their well-being at a given point of  observation[23]. Bear-
ing in mind that the questionnaire was intended for IBD 
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Table 3  Symptom questionnaire results
Symptom groups Median 
(interquartile 
range)
Minimum
value
Maximum
value
Bowel symptoms
Increased frequency of defecation 3 (2) 1 6
Abdominal cramps 3 (1) 1 5
Passing gas 4 (2) 1 7
Abdominal bloating 5 (2) 1 7
Feeling a need to defecate 3 (2) 1 7
Soiling 1 (1.25) 1 5
Stomach pain 3 (1) 1 6
Systemic symptoms
Tired and worn out 3.5 (1) 1 6
Nausea 3 (2) 1 6
Generally unwell 3 (1.25) 1 5
Sleep disturbance 4 (2) 1 7
Weight problems 3 (2.25) 1 7
Social function
Work/school activities 1 (0) 1 7
Cancel social engagements 1 (1) 1 7
Leisure/sports activity 3 (3) 1 7
Avoid events lacking toilet 1 (1) 1 4
Sexual activity 2 (2) 1 7
Emotional function
Frustrated/impatient 3 (1) 1 6
Energy 3 (2) 2 6
Fear of not finding a toilet 2 (2) 1 4
Depressed/discouraged 3 (1) 1 5
Worried about illness 3 (1.25) 1 7
Relaxed/free from worries 5 (1) 2 7
Tearful or upset 2 (1.25) 1 5
Angry 3 (2) 1 7
Irritable 3 (2) 1 5
Lack of understanding by others 2 (1) 1 6
Satisfaction with personal life 4 (2) 1 6
Figure 1  Principal component analysis of bacterial data and patient symp-
tom scores. A: Dimension 1 explains 20.4% of the observed variation among 
test subjects when bacterial data and symptom groups are studied. The four 
symptom groups have correlations with Dimension 1 of 0.77-0.63, all with P < 
0.001, and Ruminococcus torques 94% has a correlation of 0.58, with P < 0.001. 
Coprococcus eutactus 97%, Bifidobacterium spp., Veillonella spp. and Desulfovi-
brio desulfuricans-group also present significant, albeit smaller, negative correla-
tions with Dimension 1; B: When the bowel symptom sum is studied question-
wise, individual symptoms (except for soiling) as well as Ruminococcus torques 
94% show a significant correlation of 0.57-0.75, with P < 0.001, with Dimension 
1. Negative associations are observed for Collinsella aerofaciens-like, Coprococ-
cus eutactus 97%, Veillonella spp., Lactobacillus spp. and Bifidobacterium spp.
Table 4  Mean values and Spearman correlations (rs) of symp-
tom groups
Variable mean 
(SD)
Bowel 
symptoms rs
Systemic 
symptoms rs
Social 
symptoms rs
Bowel symptoms 24.0 (6.5) - - -
Systemic symptoms 16.4 (8.1) 0.58b - -
Social function   9.3 (4.3) 0.60b 0.34a -
Emotional function 39.9 (8.1) 0.71b 0.76b 0.58b
aP < 0.05, bP < 0.001.
C. coccoides -group
R. torques 94%
R. torques 91%
C. eutactus 97%
B. catenulatum
C. cocleatum 88%
C. aerofaciens
Bifidobacterium 
Veillonella 
Lactobacillus
Desulfovibrio 
S. bovis
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Systemic symptoms
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               Dim 1 (22.41%)
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               Dim 1 (22.1%)
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C. aerofaciens
Bifidobacterium 
C. eutactus 97%R. torques 91%
B. catenulatumVeillonella 
C. cocleatum 88%
Lactobacillus
Desulfovibrio S. bovis
R. torques 94%
C. coccoides -group
Soiling
Bloating
Passing gas
Increased need to defecate/need 
to defecate when bowel is empty
Abdominal cramps
Abdominal pain
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patients, the results should be interpreted with caution. For 
example, reasons underlying weight problems are different 
in IBS patients than in IBD patients, who may experience 
problems with either loss or gain of  weight, depending on 
the status of  their disease[24]. In our study, weight problems 
were correlated with a higher BMI and can thus be con-
sidered a measure of  problems with weight. Division of  
the patients into two groups according to the BMI values 
resulted in a significant divergence (P < 0.01) in the sys-
temic symptom scores between these two groups, with the 
patients having a BMI in excess of  25 experiencing more 
symptoms than leaner subjects. This observation may sug-
gest that some variables other than severity of  IBS might 
be affected by BMI, as seemed to be the case for lactoba-
cilli and bifidobacteria (Table 5). In addition, as some of  
the participants were treated for hypertension, any connec-
tions between blood pressure and GI microbiota should 
be observed with extreme caution.
C. aerofaciens-like phylotype had interesting associa-
tions with patient characteristics. We have previously 
observed a reduction in the amount of  C. aerofaciens in 
the fecal samples of  IBS patients compared with healthy 
controls[4]. Recently, Mäkivuokko et al[25] reported that 
elderly subjects using non-steroidal anti-inflammatory 
drugs (NSAIDs) had reduced amounts of  C. aerofaciens 
present in their feces relative to healthy young subjects 
and elderly subjects without NSAIDs. A link between 
anti-inflammatory drugs and the absence of  C. aerofaciens 
was suggested by the authors. In this present study, we 
observed a negative correlation between the presence 
(or amounts) of  C. aerofaciens and the BMI value of  test 
subjects. Notably, obese (BMI > 30) subjects were nega-
tive for C. aerofaciens, but contradictory to our results, 
Turnbaugh et al[26] have found C. aerofaciens to be more 
prominent in obese than lean twins and their mothers. 
Obesity has been associated with a low-grade systemic 
inflammation in which the GI microbiota may be in-
volved[27]; this could explain the negative association ob-
served for C. aerofaciens and BMI values. It was difficult 
to conclude whether C. aerofaciens could have any role in 
IBS; in general, overweight (BMI > 25) subjects reported 
more systemic symptoms than normal-weight subjects. 
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Table 5  Number of 16S rRNA gene copies detected in 50 ng of fecal DNA
qPCR assay All (n  = 44) BMI < 251 (n  = 17) BMI > 25 (n  = 22) P 2
Bifidobacterium catenulatum/Pseudocatenulatum-like  4.8 (1.6)3 5.4 (0.7) 4.3 (1.8) 0.366
Bifidobacterium spp. 5.8 (1.0) 5.5 (1.0) 6.2 (0.9) 0.009
Clostridium coccoides/Eubacterium rectale-group 7.3 (0.2) 7.3 (0.1) 7.3 (0.2) 0.630
Clostridium cocleatum 88% 5.6 (1.1) 5.5 (1.4) 5.6 (1.0) 0.483
Collinsella aerofaciens-like 5.6 (1.1) 5.3 (1.2) 5.8 (0.9) 0.294
Coprococcus eutactus 97% 5.3 (1.5) 5.5 (1.7) 5.4 (1.3) 0.639
Desulfovibrio desulfuricans-group 3.9 (0.8) 3.8 (0.6) 4.0 (0.9) 0.403
Eubacterial 16S 6.0 (0.3) 5.9 (0.4) 6.0 (0.3) 0.630
Lactobacillus-group 3.9 (0.9) 4.2 (0.7) 3.7 (0.9) 0.060
Ruminococcus torques 91% 4.6 (0.8) 4.4 (0.8) 4.8 (0.7) 0.461
Ruminococcus torques 94% 3.8 (1.0) 4.0 (1.3) 3.6 (0.8) 0.409
Streptococcus bovis-like 2.7 (1.5) 3.2 (2.1) 2.5 (1.2) 0.732
Veillonella spp. 3.4 (1.0) 3.5 (1.1) 3.4 (1.1) 0.745
1Body mass index (BMI) data missing for 5 subjects; 2Calculated with Mann-Whitney U-test; 3Values are presented as log10 averages with standard devia-
tion in parentheses. qPCR: Quantitative real-time polymerase chain reaction.
Table 6  Prevalence of target 16S rRNA genes detected for each quantitative real-time polymerase chain reaction assay
qPCR assay All (n  = 44) BMI < 251 (n  = 17) BMI > 25 (n  = 22) P 2
Bifidobacterium catenulatum/Pseudocatenulatum 12   3   7 0.315
Bifidobacterium spp. 44 17 22 ND
Clostridium coccoides/Eubacterium rectale-group 44 17 22 ND
Clostridium cocleatum 88% 33 13 15 0.568
Collinsella aerofaciens-like 29 15 12 0.024
Coprococcus eutactus 97% 16   7   8 0.759
Desulfovibrio desulfuricans-group 29 11 15 0.819
Eubacterial 16S 44 17 22 ND
Lactobacillus-group 44 17 22 ND
Ruminococcus torques 91% 38 15 18 0.582
Ruminococcus torques 94% 29   9 16 0.202
Streptococcus bovi-like 33 11 18 0.225
Veillonella spp. 41 16 20 0.709
1Body mass index (BMI) data missing for 5 subjects; 2Calculated with pearson c2 test. ND: Not determined; qPCR: Quantitative real-time polymerase chain 
reaction.
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This leads to a problem in interpretation of  the results; 
as the measured symptom groups correlate strongly with 
each other, it is difficult to determine whether a rise ob-
served in one symptom group is actually caused by a rise 
in another symptom group rather than by IBS itself.
The phylogenetically most similar species to R. torques 
94% which has previously been associated with IBS-D[18] 
is a known mucin degrader[28], and the reported increase 
of  mucin in the context of  IBS could explain the ob-
served link between this phylotype and the symptoms. 
The negative association of  R. torques 94% with C. coclea-
tum 88%, C. aerofaciens-like and C. eutactus 97%, observed 
for this phylotype could thus also be due to sample char-
acteristics (i.e. abundance of  mucus and human cells in 
the samples) and is in correlation with previous results, 
as these phylotypes have been associated with healthy 
controls’ GI microbiota in comparison with that of  IBS 
subjects[4]. However, with our knowledge being restricted 
to the 16S ribosomal DNA sequence of  the phylotype, 
all suggestions about the functions of  these bacteria 
should be considered merely speculative.
Regarding R. torques 94%, an association with BMI 
values was lacking, while a role for this phylotype in IBS 
was suggested (Figure 1A and B). Of  the bacterial gen-
era and phylotypes here negatively associated with symp-
tom scores or bowel symptoms (Figure 1A and B), Lacto-
bacillus spp., Bifidobacterium spp., D. desulfuricans-group, C. 
aerofaciens-like and C. eutactus 97% have previously been 
detected in lowest quantities among IBS-D patients in 
comparison to other IBS symptom subtypes and healthy 
control subjects[5,18]. Veillonella spp. has previously been 
associated with constipation-predominant IBS subjects[5] 
but was not found to correlate with self  reported IBS 
symptoms in this study. 
The observed higher abundance of  Bifidobacterium 
spp. in overweight subjects has previously been reported 
in a large metagenomic study[26]. Interestingly, an energy-
restricted diet has been shown to reduce C. coccoides-
group, Bifidobacterium longum and Bifidobacterium adolescentis 
counts and increase Bacteroides fragilis- and Lactobacillus-
group counts in originally overweight adolescents, with 
the effect being more pronounced among subjects who 
had lost more weight[29]. However, as Santacruz et al[29] 
concluded, it may well be the proportional amounts of  
various bacterial groups within the GI tract rather than 
their absolute numbers that play a role or react in com-
plex events within the GI tract; they found the Bifidobac-
terium to C. coccoides-group ratio to increase in correlation 
with weight loss. In our study, the C. coccoides/E. rectale-
group levels were the same in normal-weight and over-
weight subjects (Table 5).
In conclusion, our findings indicate that certain bacte-
rial phylotypes might serve as markers of  symptom sever-
ity in IBS. While the presence of  R. torques 94% was as-
sociated with an increase in symptom severity, some other 
phylotypes seemed to act in the opposite direction. These 
microbes are, however, not found in all individuals and 
they may also be present in healthy subjects’ samples[4]; 
therefore it is unlikely that their presence or absence in the 
GI tract would be the underlying cause of  IBS.
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Background
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disor-
der and results in a reduced quality of life. Alterations in the human GI microbiota 
have been detected among patients suffering from the syndrome. The abnormali-
ties in the GI microbiota are suggested to contribute to IBS symptoms.
Research frontiers 
The role of GI microbiota in IBS has been under investigation and studies 
suggest that microbes associated with IBS possess potential as non-invasive 
biomarkers. Since the majority of the GI bacteria are uncultivable, molecular 
methods are crucial in this field and have enabled a deeper study of the dis-
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Table 7  Association of Ruminococcus torques 94% phylotype 
with bowel symptoms and other fecal bacterial phylotypes
Variable All 
samples
Ruminococcus torques  94%
Detected Undetected
Symptom sums1
All symptoms   83.6 (20.0)   87.6 (19.6)  75.9 (19.1)
Bowel symptoms 24.1 (6.5) 25.4 (6.5)   21.5 (5.8)2,3
Systemic symptoms 16.4 (4.8) 17.0 (4.7) 15.2 (4.8)
Social function   9.3 (4.3) 10.0 (4.5)   7.8 (3.6)
Emotional function 33.9 (8.1) 35.2 (8.0) 31.5 (7.9)
qPCR assays4
Bifidobacterium catenulatum/
Pseudocatenulatum 
  2.5 (1.7)   2.5 (1.7)   2.5 (1.6)
Bifidobacterium spp.   5.8 (1.0)   5.8 (1.0)   5.9 (1.1)
Clostridium coccoides 
/Eubacterium rectale-group
  7.3 (0.2)   7.3 (0.2)   7.3 (0.2)
Clostridium cocleatum 88%   3.9 (2.8)   3.1 (3.0)    5.4 (1.7)5
Collinsella aerofaciens-like   3.0 (3.8)   1.6 (4.0)    5.6 (0.7)5
Coprococcus eutactus 97%   1.9 (2.8)   0.9 (2.2)    3.7 (3.0)6
Desulfovibrio 
desulfuricans-group
  1.9 (3.0)   1.4 (3.1)   2.7 (2.6)
Eubacterial 16S   6.0 (0.3)   5.9 (0.3)   6.0 (0.4)
Lactobacillus-group   3.9 (0.9)   3.8 (0.8)   4.1 (1.0)
Ruminococcus torques 91%   4.1 (1.5)   4.1 (1.6)   3.9 (1.3)
Ruminococcus torques 94%   2.7 (1.8)   3.8 (1.0) -
Streptococcus bovis-like   1.9 (1.9)   1.6 (1.6)   2.4 (2.3)
Veillonella spp.   3.0 (1.7)   3.2 (1.7)   3.0 (1.8)
1Values are presented as averages with standard deviation in parentheses; 
2All statistical comparisons made between samples with Ruminococcus 
torques 94% detected and undetected; 3Significant difference (P < 0.05) using 
analysis of variance (ANOVA) test with continuous data; 4The values are 
presented as log10 averages with standard deviation in parentheses; 5Signif-
icant difference (P < 0.05) using ANOVA test with binary data; 6Significant 
difference (P < 0.01) using ANOVA test with binary data.
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turbed microbiota. The authors examined whether the quantities, or presence 
or absence, of certain microbes previously linked to either IBS or healthy micro-
biota, correlated with the symptoms experienced by IBS patients.
Innovations and breakthroughs
Alterations in the overall microbiota and certain microbial phylotypes have been 
detected in IBS. The results of this study suggest that there is a connection 
between IBS-related microbiota and severity of self-reported symptoms.
Applications 
The findings in this study indicate that certain bacterial phylotypes are associ-
ated with symptom severity in IBS. These bacteria may serve as biomarkers of 
the course of the condition.
Terminology
Human intestinal microbiota is the ensemble of all microbes in the gastrointes-
tinal tract. The term bacterial phylotype stands for an operative taxonomic unit 
determined by the 16S rRNA gene sequence similarity. Quantitative real-time 
polymerase chain reaction (qPCR) is a method that enables quantification of 
target DNA molecules in a sample. In this study 16S rDNA sequences of known 
bacterial genera and of bacterial phylotypes were quantified using qPCR. 
Peer review
This paper represents a large amount of work. Although the results are largely 
negative, they should be published, since IBS is such an important issue.
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